T5 Advisors (T5) is a consultancy comprised of multi-functional leaders that have created a collaborative, independent approach to address the complex challenges patients face in gaining access to high-cost, therapies for complex and rare diseases. Our consultancy is patient centric and uniquely capable of meeting the needs of the patient / provider / manufacturer / payer / reinsurer ecosystem simultaneously. Since the Fall of 2021 T5 have been signing NDAs and engaging with leaders from biopharma manufacturers, healthcare providers, commercial insurers/payers, reinsurers, and others, in proposing ways today’s ecosystem can realize a sustainable, comprehensive solution for the clinical, operational, and financial challenges associated with treating patients with gene and cell altering medications. We have learned there is genuine interest in our approach and we are developing a bold solution through a series of consulting services to address specific as well as broader systemic issues that these organizations face today. Our first pilot initiative will be available this fall (2023).
With our partners, we enable patient access and overcome previously intractable barriers to clinical, financial, and operational delivery and use of these therapies.
Our unique and innovative technology uses a rules-based engine, up-to-date treatment solutions, and current best practices to maximize the experience for the patient and providers.